Real-world Effectiveness of Adalimumab on Health Outcomes in Chinese Patients With Immune-Mediated Inflammatory Diseases (ADMIT)

AbbVie

Status

Completed

Conditions

Psoriasis

Ankylosing Spondylitis (AS)

Rheumatoid Arthritis (RA)

Study type

Observational

Funder types

Industry

Identifiers

NCT03339089

P16-828

Details and patient eligibility

About

The objective of this study is to evaluate the effect of adalimumab on health outcomes in participants with rheumatoid arthritis, ankylosing spondylitis and plaque psoriasis.

Enrollment

224 patients

Sex

All

Ages

18 to 99 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Participants with a diagnosis of rheumatoid arthritis, ankylosing spondylitis or plaque psoriasis
Decision to initiate Humira® treatment in accordance with routine medical practice and in compliance with eligibility for adalimumab based on the local label
Prior to any study-specific procedures, participant has voluntarily signed the authorization (or informed consent where applicable) to disclose and use anonymized personal health information after participate in this research.

Exclusion criteria

Inadequate response to previous standard treatment with anti-tumor necrosis factor (TNF) biological agent according to the physician's clinical judgment.
Participant has been treated with adalimumab within 70 days (five half-lives) prior to the Baseline Visit.
Participants discontinued due to adverse drug reaction of previous adalimumab treatment.
Participants who fulfill any of the contraindications as per adalimumab label in China.
Participants, who in the clinician's view, may not be able to comply with the study requirements.